DIXA
10.3.2022 11:32:05 CET | Business Wire | Press release
Danish customer support innovator Dixa has today announced the acquisitions of analytics leader Miuros , and automation pioneer Solvemate . Driven by a need amongst service teams to connect to customers with intelligence, empathy, and the right information, the double acquisition is valued at $43 million and strengthens Dixa’s long-term vision to set a new standard in experience and data-driven conversational customer service, giving brands the toolkit they need to utilize data on a new scale for automation, measurement and analytics.
Dixa is used by consumer-facing and digital-first brands to serve customers across multiple channels, touchpoints and experiences from a single screen including social media, chat, voice and messaging apps, enabling an outstanding experience for both customers and agents. With cross-channel prioritization features, powerful routing capabilities, and flexible integrations, Dixa helps brands across the globe deliver value-driven customer experiences at scale, all from a single platform.
Solvemate builds in a powerful self-service layer into the platform that ensures brands can create a painless customer experience with the power of AI to give instant, personal, reliable answers via any customer-facing channel, or funnel requests to the right agent. Its introduction means users can now handle the end-to-end customer journey in a more intelligent, automated and conversational way, while also improving the agent experience through more seamless bot-to-agent handovers.
Miuros was designed to help brands turn customer data into actionable insights with AI-powered analytics, quality assurance and automation. Its addition to the Dixa platform will allow service leaders to harness the power of this technology and gain a better, more comprehensive understanding of the service function. Underpinned by Dixa’s data-rich foundation, service leaders will be able to make stronger, data-informed decisions, such as spotting and acting upon trends in agent productivity and sentiment.
“To create value-driven experiences, brands need a complete platform that leverages data, AI and machine learning to deliver the right knowledge to customers, support agents and internal teams at the right time,” said Mads Fosselius, CEO and co-founder of Dixa. “In being able to draw on our data-rich foundation and existing knowledge base, Elevio, the addition of Miuros and Solvemate will allow service leaders to leverage data on a new scale for automation, measurement and insights from a single platform, setting an entirely new standard in data-driven customer service.”
Dixa’s acquisition rounds out an impressive service offering that also includes a new, bespoke messaging product that delivers rich messaging across web, mobile, and app environments. Dixa Messenger will launch in March 2022, joining native telephony, email, and social messaging support on Dixa’s platform.
“Dixa Messenger is a powerful new service desk for your brand, allowing customer loving teams to create great experiences wherever your customers are,” says Rob Krassowski, Dixa’s VP of Product, “Solvemate and Miuros allow us to take a more data-driven approach to automation and self-service, plus give service agents the tools that they need to create compelling experiences for customers and real business value for their brands.”
Erik Pfannmöller, CEO & Co-founder from Solvemate added: “Powered by smart conversational AI, Solvemate allows brands to create highly personalized chatbot conversations at scale, guiding customers to find answers when they need them. Reducing the number of common, repetitive requests handled by agents means that service teams can focus their expertise where it matters most: solving the more complex cases which require a human touch. By giving consumers faster solutions and taking away noise for agents, we share Dixa’s ambition to service a multiexperience world for delivering unparalleled customer service.”
Benoit Gagnon, CEO & Co-founder from Miuros said: “Dixa is the only platform that can turn a traditional customer service organization into a value creation team by elevating both the agent and customer experience, and we’re delighted to be joining during such an exciting period. Miuros was designed to bring customer service data to life, creating actionable insights to streamline operations, as well as empowering the whole company to create an outstanding customer experience. By adding Miuros’ analytics capabilities, service leaders will now be able to optimize their operations through AI and obtain actionable insights, without needing to stitch together multiple siloed solutions.”
Solvemate, with a global customer base of over 100 brands such as On, JustPark, Sport24, Holidu and CreditPlus, was founded in 2015 by co-founders Erik Pfannmöller, Jürgen Vogel and Christian Blomberg. Miuros, with a global customer base of over 100 mid-market and enterprise brands, including Deezer, Wise, About You, Freenow and Swapfiets, was founded in 2016 by co-founders Benoit Gagnon, Dr. Ricardo De Aldama and Daniele Alfarone. Solvemate and Miuros will continue to service their current customers across platforms in addition to expanding on existing integrations with Dixa.
Dixa has raised $155 million in funding to date with backing from Notion Capital, Project A Ventures, SEED Capital and recently from General Atlantic. The company has offices in Copenhagen, London, Berlin, Paris, Chicago, Tallinn, Kiev, Tel Aviv and Melbourne.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220310005038/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
